- US-listed companies
- REGENERON PHARMACEUTICALS, INC.
REGENERON PHARMACEUTICALS, INC.REGN
Market cap
$125.7B
P/E ratio
31.8x
Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
Product | - | - | - | - | - | - | - | - | 4,106 | 4,834 | 5,568 | 12,117 | 6,894 | 7,078 |
Sanofi collaboration revenue | - | - | - | - | - | - | - | - | - | - | - | - | 2,856 | - |
Collaboration revenue | - | - | - | - | - | - | - | - | - | - | - | 1,902 | 2,058 | 5,503 |
Collaboration revenue | - | - | - | - | - | - | - | - | - | - | - | 1,902 | 2,058 | 5,503 |
Other revenue | - | - | - | - | - | - | - | - | 1,111 | 1,427 | 1,186 | 281 | 365 | 536 |
Other revenue | - | - | - | - | - | - | - | - | 1,111 | 1,427 | 1,186 | 281 | 365 | 536 |
Revenue from contract with customer | 459 | 446 | 1,378 | 2,105 | 2,820 | 4,104 | 4,860 | 5,872 | 6,711 | 7,863 | 8,497 | 16,072 | 12,173 | 13,117 |
Research and development | 489 | 530 | 626 | 860 | 1,271 | 1,621 | 2,052 | 2,075 | 2,186 | 3,037 | 2,735 | 2,908 | 3,593 | 4,439 |
Acquired in-process research and development | - | - | - | - | - | - | - | - | - | - | - | - | 255 | 186 |
Selling, general, and administrative | 65 | 117 | 211 | 329 | 505 | 839 | 1,178 | 1,320 | 1,556 | 1,835 | 1,346 | 1,825 | 2,116 | 2,631 |
Product | - | - | - | - | - | - | - | - | 180 | 362 | 492 | 1,773 | 800 | 932 |
Cost of collaboration and contract manufacturing | - | - | - | - | - | - | - | - | 254 | 420 | 628 | 664 | 760 | 884 |
Cost of collaboration and contract manufacturing | - | - | - | - | - | - | - | - | 254 | 420 | 628 | 664 | 760 | 884 |
Other operating (income) expense, net | - | - | - | - | - | - | - | - | - | - | 280 | 46 | 90 | 2 |
Total expenses | 557 | 651 | 921 | 1,345 | 1,981 | 2,852 | 3,530 | 3,793 | 4,176 | 5,654 | 4,921 | 7,125 | 7,434 | 9,070 |
Income from operations | -97 | -205 | 458 | 760 | 838 | 1,252 | 1,331 | 2,080 | 2,534 | 2,210 | 3,577 | 8,947 | 4,739 | 4,047 |
Other income (expense), net | - | - | - | - | - | 6 | 6 | 24 | 47 | 250 | 291 | 436 | 179 | 225 |
Interest expense | 9 | 21 | 45 | 46 | 37 | 14 | - | - | 28 | 30 | 57 | 57 | 59 | 73 |
Total other income (expense) | -7 | -18 | -43 | -47 | -63 | -27 | -1 | -1 | 19 | 219 | 234 | 379 | 120 | 152 |
Income before income taxes | -104 | -223 | 414 | 713 | 776 | 1,225 | 1,330 | 2,079 | 2,554 | 2,429 | 3,810 | 9,326 | 4,859 | 4,199 |
Income tax expense | - | -1 | -336 | 289 | 428 | 589 | 434 | 880 | 109 | 313 | 297 | 1,251 | 520 | 246 |
Net income | -104 | -222 | 750 | 424 | 348 | 636 | 896 | 1,199 | 2,444 | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 |
Earnings Per Share, Basic | - | - | 7.92 | 4.33 | 3.46 | 6.17 | 8.55 | 11.27 | 22.65 | 19.38 | 32.65 | 76.4 | 40.51 | 37.05 |
Earnings Per Share, Diluted | - | - | 6.75 | 3.81 | 3.07 | 5.52 | 7.7 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 |
Net income | -104 | -222 | 750 | 424 | 348 | 636 | 896 | 1,199 | 2,444 | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 |
Unrealized gain (loss) on debt securities | - | - | 1 | -0 | 53 | -44 | -21 | 13 | -7 | 36 | 9 | -56 | -214 | 158 |
Unrealized gain on cash flow hedges | - | - | - | - | - | - | - | - | - | -2 | -1 | 1 | 1 | - |
Loss on foreign currency translation | - | - | - | - | - | - | - | - | - | - | - | - | - | -0 |
Unrealized gain on cash flow hedges | - | - | - | - | - | - | - | - | - | -2 | -1 | 1 | 1 | - |
Comprehensive income | - | - | 751 | 424 | 402 | 592 | 874 | 1,212 | 2,438 | 2,149 | 3,521 | 8,020 | 4,126 | 4,112 |